Cumberland Pharmaceuticals Inc. CPIX
4.20 USD -0.11 (-2.55%)
Nov 4, 2026, 11:29 AM EST
4.15 Day range 4.37
1.85 52-week range 9.28
- YTD
- +5.53%
- 1 year
- +57.90%
News
prnewswire.com CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q3 2026 FINANCIAL RESULTS NASHVILLE, Tenn., Nov. 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases,…
seekingalpha.com Cumberland Pharmaceuticals Inc. (CPIX) Discusses Duchenne Cardiomyopathy NDA Submission and Product Development Strategy Prepared Remarks Transcript Cumberland Pharmaceuticals Inc. (CPIX) Discusses Duchenne Cardiomyopathy NDA Submission and Product Development Strategy Prepared Remarks Transcript
marketbeat.com Cumberland Pharmaceuticals Begins Rolling FDA NDA for Dyscorban in Duchenne Cardiomyopathy Cumberland Pharmaceuticals NASDAQ: CPIX said it plans to begin a rolling New Drug Application submission for Dyscorban, its ifetroban candidate for cardiomyopathy associated with Duchenne muscular…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Senti Biosciences (NASDAQ:SNTI) stock rose 51.8% to $0.27 during Monday's after-market session. The company's market cap stands at $5.9 million. Polyrizon (NASDAQ:PLRZ) shares increased by…
benzinga.com Cumberland Pharmaceuticals Intends To File New Drug Application To FDA For Ifetroban To Treat Cardiomyopathy Associated With Duchenne Muscular Dystrophy Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), ("Cumberland" or the "Company") an innovation-focused biopharmaceutical company developing new products for rare diseases, today provided an update on…
prnewswire.com CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM NASHVILLE, Tenn., Oct. 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), ("Cumberland" or the "Company") an innovation-focused biopharmaceutical company developing new products…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares…
benzinga.com Cumberland Pharmaceuticals Announces Data From Its Phase 2 ASSIST-SSc Study Of Oral Ifetroban For Patients With Systemic Sclerosis; Gastrointestinal Adverse Events Were More Frequent In Ifetroban Group Than Placebo; Majority Of Patients Demonstrated Limited Disease Progression, Which Reduced Ability To Track Treatment Difference Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announces top-line results from…
prnewswire.com Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results Ifetroban was well tolerated in patients with systemic sclerosis NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical…
prnewswire.com CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet…
prnewswire.com CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM NASHVILLE, Tenn., Oct. 19, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet…
defenseworld.net Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Crosses Above 200 Day Moving Average – What’s Next? Shares of Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX - Get Free Report) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $5.62 and…
defenseworld.net Contrasting ANI Pharmaceuticals (NASDAQ:ANIP) and Cumberland Pharmaceuticals (NASDAQ:CPIX) Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and ANI Pharmaceuticals (NASDAQ: ANIP - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will…
seekingalpha.com Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity Cumberland Pharmaceuticals Inc. has transformed from a commercial-stage pharma to a pre-revenue, Phase 2-stage biotech focused on rare diseases. Recent $100M asset sale to Apotex funds operations and…
defenseworld.net Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above Two Hundred Day Moving Average – Should You Sell? Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX - Get Free Report) passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $4.87 and traded as high…
seekingalpha.com Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript
marketbeat.com Cumberland Pharmaceuticals Q2 Earnings Call Highlights Cumberland Pharmaceuticals NASDAQ: CPIX reported a second-quarter operating loss of $3.1 million as it prepared to transition from a commercial-stage specialty pharmaceutical company into an…- benzinga.com Cumberland Q2 Adj. EPS $(0.20) Down From $(0.13) YoY, Sales $166.458K Down From $380.797K YoY Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.20) per share. This is a 53.85 percent decrease over losses of $(0.13) per share from the same period last year. The company reported…
prnewswire.com CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS $100 million Strategic Transaction Closed Special Shareholder Dividend Funded Advancing Late Stage Clinical Pipeline NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.…- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 million. Supernus…
zacks.com Possible Generic Drug Tariffs and 2 Microcaps Generic drug tariffs could impact ELTP and CPIX.
prnewswire.com CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS NASHVILLE, Tenn., July 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases,…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market session. The company's market cap stands at $66.4 million. ProMIS Neurosciences (NASDAQ:PMN) shares…
zacks.com ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now? Elite Pharmaceuticals and Cumberland Pharmaceuticals follow different growth paths, but which looks more compelling now? Let's dive in.
gurufocus.com /C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./ /C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./ PR Newswire NASHVILLE, Tenn., July 13, 2026
gurufocus.com CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE PR Newswire NASHVILLE, Tenn., July 13,
benzinga.com Cumberland Pharmaceuticals Declares $1.50/Share Special Dividend Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized…
prnewswire.com CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE Record Date is July 10, 2026 & Payment Date is July 31,2026 Corporate and Insider Share Purchase Initiatives to Continue NASHVILLE, Tenn., July 13, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals…
benzinga.com Cumberland Pharma Advances Duchenne Program With New Safety, Efficacy Data Cumberland Pharma shares rose after Phase 2 data showed ifetroban improved heart function in Duchenne muscular dystrophy patients.
benzinga.com Redhill Biopharma Announces FDA Rare Pediatric Disease Designation For Opaganib For The Treatment Of Neuroblastoma The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young…
benzinga.com U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Cumberland And Vanderbilt Announce Phase 2a Clinical Trial Of Ifetroban Met Primary Endpoint Demonstrating Safety And Tolerability Of Ifetroban In Patients With High-Risk Solid Tumors Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising efficacy…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Why e.l.f. Beauty Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket Shares of elf Beauty Inc (NYSE: ELF) rose sharply in pre-market trading after beating analyst expectations with fourth-quarter earnings of 32 cents per share and revenue of $449.29 million, up 35%.…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Full Transcript: Cumberland Q1 2026 Earnings Call
benzinga.com Cumberland Q1 Adj. EPS $(0.13) Down From $0.16 YoY, Sales $9.131M Down From $11.713M YoY Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.13) per share. This is a 181.25 percent decrease over earnings of $0.16 per share from the same period last year. The company reported $9.131…
benzinga.com Earnings Scheduled For May 5, 2026 
benzinga.com Why Sterling Infrastructure Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket Shares of Sterling Infrastructure Inc (NASDAQ: STRL) jumped 22.5% in pre-market trading after reporting better-than-expected Q1 results and raising its FY26 guidance. Other gainers include BLZE,…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Crude Oil Gains Over 1%; US Initial Jobless Claims Edge Higher US stocks down, Nasdaq falls 0.4% on Thursday. Jobless claims rise to 214,000. Utilities jump 2.1%, ServiceNow shares drop 16%.
benzinga.com Dow Falls Over 200 Points; Tesla Shares Slip After Q1 Results Dow Jones drops 0.44%, NASDAQ falls 0.31%, S&P 500 down 0.22%. Tesla shares drop 1% after reporting earnings. Auddia Inc. and Cumberland Pharmaceuticals Inc. see significant gains.- benzinga.com Cumberland Pharmaceuticals Announces That Apotex Will Acquire The Company's Line Of Branded Pharmaceuticals For $100M In Cash Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a U.S. specialty pharmaceutical company, today announced it has entered into an agreement with an affiliate of Apotex ("Apotex"), the largest Canadian…
- benzinga.com Cumberland Q4 Adj. EPS $(0.01) Up From $(0.02) YoY, Sales $13.679M Up From $10.436M YoY Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.01) per share. This is a 50 percent increase over losses of $(0.02) per share from the same period last year. The company reported $13.679…
- benzinga.com Earnings Scheduled For March 3, 2026
benzinga.com FDA Grants Fast Track Designation For Cumberland Pharma's Oral Therapy Targeting Fatal Form Of Heart Disease In Duchenne Muscular Dystrophy Patients Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, announced today that the U.S. Food and Drug Administration…- benzinga.com Cumberland's Caldolor Injection Receives Permanent J-Code With Reimbursement Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), today announced an important update regarding its Caldolor® (ibuprofen) Injection. The product's permanent J-code, J1741, is now officially associated…
- benzinga.com Cumberland Q3 Adj. EPS $(0.06) Down From $(0.02) YoY, Sales $8.292M Down From $9.086M YoY Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.06) per share. This is a 200 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $8.292…